T-cell/NK-cell lymphomas: A review

Cancer Letters

Volumn 253, Issue 1, 2007, Pages 1-13

  Panwalkar, Amit W ^a   Armitage, James O ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

NK cell; Non Hodgkin's lymphoma; T cell

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ARSENIC TRIOXIDE; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IMIQUIMOD; METHOTREXATE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; RETINOIC ACID; VINBLASTINE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ELECTRON THERAPY; GENE EXPRESSION; GLUTEN FREE DIET; HUMAN; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; PHOTOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEZARY SYNDROME; SHORT SURVEY; SKIN LYMPHOMA; SURGICAL TECHNIQUE; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 34249871350     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.11.018     Document Type: Review

References (145)

1. Armitage J.O., et al. Lymphoma 2006: classification and treatment. Oncology (Williston Park) 20 3 (2006) 231-239 discussion 242, 244, 249
2. Jaffe E., et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours (2001), IARC Press, Lyon, France
3. Jaffe E.S., et al. Extranodal peripheral T-cell and NK-cell neoplasms. Am. J. Clin. Pathol. 111 1 Suppl 1 (1999) S46-S55
4. Picker L.J., et al. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am. J. Pathol. 128 1 (1987) 181-201
5. Greiner T.C., et al. Analysis of T-cell receptor-gamma gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products. Correlation with tumor-specific sequences. Am. J. Pathol. 146 1 (1995) 46-55
6. Krafft A.E., et al. Enhanced sensitivity with a novel TCRgamma PCR assay for clonality studies in 569 formalin-fixed, paraffin-embedded (FFPE) cases. Mol. Diagn. 4 2 (1999) 119-133
7. Jaffe E.S. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod. Pathol. 14 3 (2001) 219-228
8. Stein H., et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96 12 (2000) 3681-3695
9. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project, Blood, 89 (11) (1997) 3909-3918.
10. Naresh K.N., et al. Report of an international network of cancer treatment and research workshop on non-Hodgkin's lymphoma in developing countries. Blood Cells Mol. Dis. 33 3 (2004) 330-337
11. Naresh K.N., et al. Use of the world health organization (WHO) classification of non-Hodgkin's lymphoma in Mumbai, India: a review of 200 consecutive cases by a panel of five expert hematopathologists. Leuk. Lymphoma 45 8 (2004) 1569-1577
12. Raetz E.A., et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr. Blood Cancer 47 2 (2006) 130-140
13. Tubergen D.G., et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J. Clin. Oncol. 13 6 (1995) 1368-1376
14. Hoelzer D., et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99 12 (2002) 4379-4385
15. Coleman C.N., et al. Treatment of lymphoblastic lymphoma in adults. J. Clin. Oncol. 4 11 (1986) 1628-1637
16. Morel P., et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J. Clin. Oncol. 10 7 (1992) 1078-1085
17. Thomas D.A., et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104 6 (2004) 1624-1630
18. Willemze R., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 10 (2005) 3768-3785
19. Chaperot L., et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97 10 (2001) 3210-3217
20. Feuillard J., et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99 5 (2002) 1556-1563
21. Bekkenk M.W., et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann. Oncol. 15 7 (2004) 1097-1108
22. Shapiro M., et al. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am. J. Hematol. 74 1 (2003) 46-51
23. Falcao R.P., et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk. Res. 26 9 (2002) 803-807
24. Yamada O., et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br. J. Haematol. 113 1 (2001) 153-160
25. Bayerl M.G., et al. Blastic natural killer cell lymphoma/leukemia: a report of seven cases. Am. J. Clin. Pathol. 117 1 (2002) 41-50
26. Kuroda J., et al. Variable manifestation in natural killer cell leukaemia. Clin. Lab. Haematol. 25 4 (2003) 239-245
27. Yoshimasu T., et al. Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. Bone Marrow Transplant. 30 1 (2002) 41-44
28. Yamaguchi M., et al. Long-term remission of blastic natural killer-cell lymphoma after autologous peripheral blood stem-cell transplantation. Am. J. Hematol. 80 2 (2005) 124-127
29. Lukes R.J., and Collins R.D. Immunologic characterization of human malignant lymphomas. Cancer 34 4 Suppl (1974) 1488-1503
30. Matutes E., et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78 12 (1991) 3269-3274
31. Garand R., et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d'Hematologie Cellulaire. Br. J. Haematol. 103 2 (1998) 488-494
32. Matutes E., et al. Expression of TIA-1 and TIA-2 in T-cell malignancies and T-cell lymphocytosis. J. Clin. Pathol. 49 2 (1996) 154-158
33. Mercieca J., et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 12 12 (1994) 2588-2593
34. G. Hopfinger, G. Kandler, and E. Koller, T-PLL1 protocol of the German CLL Study Group (GCLLSG) - a prospective phase 2 trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab therapy. American Society of Hematology 2003.
35. Krishnan B., Matutes E., and Dearden C. Prolymphocytic leukemias. Semin. Oncol. 33 2 (2006) 257-263
36. Collins R.H., et al. Treatment of T-prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transpl. 21 6 (1998) 627-628
37. Lamy T., and Loughran Jr. T.P. Current concepts: large granular lymphocyte leukemia. Blood Rev. 13 4 (1999) 230-240
38. Loughran Jr. T.P. Clonal diseases of large granular lymphocytes. Blood 82 1 (1993) 1-14
39. Dhodapkar M.V., et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?. Blood 84 5 (1994) 1620-1627
40. Takeuchi M., et al. Spontaneous remission of large granular lymphocyte T-cell leukemia. Leukemia 13 2 (1999) 313-314
41. Loughran T.P., Kidd Jr. P.G., and Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 84 7 (1994) 2164-2170
42. Hamidou M.A., et al. Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. Am. J. Med. 108 9 (2000) 730-732
43. Osuji N., et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer (2006)
44. Gabor E.P., Mishalani S., and Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood 87 3 (1996) 1199-1200
45. Sood R., et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 91 9 (1998) 3372-3378
46. Matrai Z., et al. T-cell large granular lymphocytic leukemia associated with pure red cell aplasia, successfully treated with cyclophosphamide. Orv. Hetil. 138 33 (1997) 2075-2080
47. Rossoff L.J., et al. Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy. Chest 112 2 (1997) 551-553
48. Ruskova A., Thula R., and Chan G. Aggressive natural killer-cell leukemia: report of five cases and review of the literature. Leuk. Lymphoma 45 12 (2004) 2427-2438
49. Fernandez L.A., et al. Aggressive natural killer cell leukemia in an adult with establishment of an NK-cell line. Blood 67 4 (1986) 925-930
50. Suzuki R., et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK-cells. Leukemia 18 4 (2004) 763-770
51. Imamura N., et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br. J. Haematol. 75 1 (1990) 49-59
52. Jaffe E.S. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 87 4 (1996) 1207-1210
53. Chan J.K. Natural killer cell neoplasms. Anat. Pathol. 3 (1998) 77-145
54. Kanegane H., et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood 91 6 (1998) 2085-2091
55. Quintanilla-Martinez L., et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 96 2 (2000) 443-451
56. Su I.J., et al. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk. Lymphoma 19 5-6 (1995) 401-406
57. Kikuta H., et al. Fatal Epstein-Barr virus-associated hemophagocytic syndrome. Blood 82 11 (1993) 3259-3264
58. Bang S.M., et al. High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. Leuk. Lymphoma 46 11 (2005) 1599-1604
59. Poiesz B.J., et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77 12 (1980) 7415-7419
60. Taylor G.P. The epidemiology of HTLV-I in Europe. J. Acqui.r Immune Defic. Syndr. Hum. Retrovirol. 13 Suppl 1 (1996) S8-S14
61. Takatsuki K., Matsuoka M., and Yamaguchi K. Adult T-cell leukemia in Japan. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13 Suppl 1 (1996) S15-S19
62. Pagliuca A. Strongyloides hyperinfection in adult T-cell leukaemia/lymphoma. Br. J. Haematol. 105 1 (1999) 1
63. Taylor G.P., and Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24 39 (2005) 6047-6057
64. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br. J. Haematol. 79 3 (1991) 428-437
65. Tsukasaki K., et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 89 3 (1997) 948-956
66. Ohshima K., et al. Clonal integration and expression of human T-cell lymphotropic virus type I in carriers detected by polymerase chain reaction and inverse PCR. Am. J. Hematol. 54 4 (1997) 306-312
67. Matutes E., et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br. J. Haematol. 113 3 (2001) 779-784
68. Hermine O., et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J 3 6 (2002) 276-282
69. Besson C., et al. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk. Lymphoma 43 12 (2002) 2275-2279
70. Fukushima T., et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19 5 (2005) 829-834
71. Tsukasaki K.F.T., and Utsunomiya A. Phase III Study of VCAP-AMP-VECP vs. biweekly CHOP in aggressive adult T-cell leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study. Blood 106 11 (2005)
72. Jaffe E.S., et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am. J. Surg. Pathol. 20 1 (1996) 103-111
73. Ho F.C., et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum. Pathol. 21 10 (1990) 1041-1050
74. Jaffe E.S., et al. Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am. J. Med. 75 5 (1983) 741-749
75. Ko Y.H., et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 89 10 (2000) 2106-2116
76. Kanavaros P., et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81 10 (1993) 2688-2695
77. Liang R. Diagnosis and management of primary nasal lymphoma of T-cell or NK-cell origin. Clin. Lymphoma 1 1 (2000) 33-37 discussion 38
78. Kim G.E., et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J. Clin. Oncol. 18 1 (2000) 54-63
79. Cheung M.M., et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J. Clin. Oncol. 16 1 (1998) 70-77
80. Kim G.E., et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother. Oncol. 61 3 (2001) 261-269
81. Li C.C., et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 100 2 (2004) 366-375
82. Lee J., et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 24 4 (2006) 612-618
83. Gale J., et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J. Clin. Oncol. 18 4 (2000) 795-803
84. Smedby K.E., et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T-cell lymphoma. Gut 54 1 (2005) 54-59
85. Holmes G.K. Coeliac disease and malignancy. Dig. Liver Dis. 34 3 (2002) 229-237
86. Quintanilla-Martinez L., et al. Primary non-Hodgkin's lymphoma of the intestine: high prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases. Blood 89 2 (1997) 644-651
87. Wohrer S., et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann. Oncol. 15 11 (2004) 1680-1683
88. Farcet J.P., et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 75 11 (1990) 2213-2219
89. Gaulard P., et al. Peripheral T-cell lymphoma presenting as predominant liver disease: a report of three cases. Hepatology 6 5 (1986) 864-868
90. Cooke C.B., et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 88 11 (1996) 4265-4274
91. Gaulard P., et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am. J. Pathol. 137 3 (1990) 617-628
92. Suarez F., et al. Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am. J. Surg. Pathol. 24 7 (2000) 1027-1032
93. Belhadj K., et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102 13 (2003) 4261-4269
94. Iannitto E., et al. Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin. Br. J. Haematol. 117 4 (2002) 995-996
95. Chanan-Khan A., et al. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk. Lymphoma 45 8 (2004) 1673-1675
96. Marzano A.V., et al. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch. Dermatol. 136 7 (2000) 889-896
97. Burg G., et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N. Engl. J. Med. 325 15 (1991) 1078-1081
98. Gonzalez C.L., et al. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am. J. Surg. Pathol. 15 1 (1991) 17-27
99. Salhany K.E., et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am. J. Surg. Pathol. 22 7 (1998) 881-893
100. Massone C., et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am. J. Surg. Pathol. 28 6 (2004) 719-735
101. Hoque S.R., et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br. J. Dermatol. 148 3 (2003) 516-525
102. Diamandidou E., Cohen P.R., and Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 88 7 (1996) 2385-2409
103. Whittaker S.J., et al. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br. J. Dermatol. 149 6 (2003) 1095-1107
104. Siegel R.S., et al. Primary cutaneous T-cell lymphoma: review and current concepts. J. Clin. Oncol. 18 15 (2000) 2908-2925
105. Girardi M., Heald P.W., and Wilson L.D. The pathogenesis of mycosis fungoides. N. Engl. J. Med. 350 19 (2004) 1978-1988
106. Santucci M., et al. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European organization for research and treatment of cancer. Am. J. Surg. Pathol. 24 1 (2000) 40-50
107. Trautinger F., et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur. J. Cancer 42 8 (2006) 1014-1030
108. Willemze R., and Meijer C.J. Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol. Oncol. Clin. North Am. 17 6 (2003) 1319-1332 vii-viii
109. Liu H.L., et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J. Am. Acad. Dermatol. 49 6 (2003) 1049-1058
110. Kaufmann T.P., Coleman M., and Nisce L.Z. Ki-1 skin lymphoproliferative disorders: management with radiation therapy. Cancer Invest. 15 2 (1997) 91-97
111. Vonderheid E.C., Sajjadian A., and Kadin M.E. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J. Am. Acad. Dermatol. 34 3 (1996) 470-481
112. Rudiger T., et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's lymphoma classification project. Ann. Oncol. 13 1 (2002) 140-149
113. Fisher R.I., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328 14 (1993) 1002-1006
114. Gordon L.I., et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med. 327 19 (1992) 1342-1349
115. Tsimberidou A.M., et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 100 2 (2004) 342-349
116. Kurzrock R. Therapy of T cell lymphomas with pentostatin. Ann. N.Y. Acad. Sci. 941 (2001) 200-205
117. Monfardini S., et al. Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Oncology 53 2 (1996) 163-168
118. Zinzani P.L., et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann. Oncol. 9 12 (1998) 1351-1353
119. Sallah S., Wan J.Y., and Nguyen N.P. Treatment of refractory T-cell malignancies using gemcitabine. Br. J. Haematol. 113 1 (2001) 185-187
120. Talpur R., et al. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk. Lymphoma 43 1 (2002) 121-126
121. LeMaistre C.F., et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91 2 (1998) 399-405
122. Dang N.H., et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 22 20 (2004) 4095-4102
123. Enblad G., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103 8 (2004) 2920-2924
124. Siegert W., et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann. Oncol. 6 7 (1995) 659-664
125. Anagnostopoulos I., et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80 7 (1992) 1804-1812
126. Reiser M., et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk. Lymphoma 43 4 (2002) 805-811
127. Sallah S., and Gagnon G.A. Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment. Acta Haematol. 99 2 (1998) 57-64
128. Siegert W., et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann. Intern. Med. 117 5 (1992) 364-370
129. Advani R., et al. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann. Oncol. 8 6 (1997) 601-603
130. Tsatalas C., et al. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta Haematol. 105 2 (2001) 106-108
131. Quintini G., et al. Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma. Hematol. J. 2 6 (2001) 393-395
132. Melnyk A., et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89 12 (1997) 4514-4520
133. Falini B., et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93 8 (1999) 2697-2706
134. Gascoyne R.D., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93 11 (1999) 3913-3921
135. Suzuki R., et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96 9 (2000) 2993-3000
136. Schlette E.J., et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J. Clin. Oncol. 22 9 (2004) 1682-1688
137. Weisenburger D.D., et al. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. Blood 87 9 (1996) 3860-3868
138. Bai R.Y., et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96 13 (2000) 4319-4327
139. Zinzani P.L., et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J. Clin. Oncol. 14 3 (1996) 955-962
140. Buttgereit P., et al. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. Cancer. Gene. Ther. 8 6 (2001) 430-439
141. Nagata S., et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin. Cancer Res. 8 7 (2002) 2345-2355
142. Moura I.C., et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103 5 (2004) 1838-1845
143. Harvey S., et al. Interactions between 2-fluoroadenine 9-beta-d-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin. Cancer Res. 7 2 (2001) 320-330
144. Blackhall F.H., et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br. J. Cancer. 84 4 (2001) 465-469
145. Piekarz R.L., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98 9 (2001) 2865-2868